Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22793463 | 1.00 | L3MBTL3 (0.33) | L3MBTL3NPY1RPARP1CCR5 | |
| SCHEMBL3421688 | 0.83 | PIK3CD (0.41) | L3MBTL3NPY1RCCR5 | |
| SCHEMBL22550662 | 0.83 | KCNH2 (0.34) | L3MBTL3NPY1R | |
| SCHEMBL19981999 | 0.81 | L3MBTL3 (0.32) | L3MBTL3NPY1RPARP1 | |
| SCHEMBL22550643 | 0.78 | UBE2M (0.35) | L3MBTL3NPY1R | |
| SCHEMBL22550363 | 0.78 | UBE2M (0.35) | L3MBTL3NPY1R | |
| SCHEMBL13349302 | 0.78 | L3MBTL3 (0.38) | L3MBTL3NPY1RPARP1CCR5 | |
| SCHEMBL27013848 | 0.76 | OPRD1 (0.33) | L3MBTL3NPY1RCCR5 | |
| SCHEMBL21535369 | 0.76 | HTT (0.33) | L3MBTL3CCR5 | |
| SCHEMBL24607412 | 0.75 | KCNA3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200325177-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-15 | — | — | US | disclosed |
| WO-2019028084-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325177-A1 | METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | PLG, LIPA, MB | L3MBTL3 2837/4885NPY1R 4221/4885PARP1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.